ACHV Stock Risk & Deep Value Analysis
Achieve Life Sciences Inc
DVR Score
out of 10
What You Need to Know About ACHV Stock
We analyzed Achieve Life Sciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ACHV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ACHV Risk Analysis & Red Flags
What Could Go Wrong
The FDA could issue a Complete Response Letter (CRL) on the June 20, 2026 PDUFA date for the smoking cessation NDA, which would likely delay commercialization by 1-2 years and require further investment, depleting their current ~$190M cash runway (as of April 30, 2026, post-private placement) much faster than planned.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Pre-revenue status with consistent quarterly net losses (Q1 2026 net loss of $10.2M), relying heavily on external funding until commercialization.
- ⚠
High dependence on the successful regulatory approval and commercialization of a single investigational drug, cytisinicline, for all near-term revenue generation.
- ⚠
Significant share dilution from the recent $168.6M private placement, impacting per-share valuation until substantial revenue is generated.
Upcoming Risk Events
- 📅
June 20, 2026: FDA issues a Complete Response Letter (CRL) for the smoking cessation NDA, delaying approval by 1-2 years or requiring additional clinical trials.
- 📅
Q3 2026 - Q1 2027: Slower-than-expected commercial ramp-up post-approval, leading to missed initial sales targets or higher-than-anticipated commercialization expenses.
When to Reconsider
- 🚪
FDA issues a Complete Response Letter (CRL) for the smoking cessation NDA on or before June 20, 2026.
- 🚪
Cash, cash equivalents, and marketable securities fall below $50M, indicating an unsustainable cash burn or a failure to secure additional financing.
- 🚪
Quarterly operating expenses increase by more than 20% sequentially without clear progress toward commercialization or regulatory approval.
Unlock ACHV Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If cytisinicline secures FDA approval for smoking cessation on June 20, 2026, and effectively leverages its differentiated safety/efficacy profile to capture 5-10% of the multi-billion dollar smoking cessation market, followed by subsequent approval and commercialization for vaping cessation (aided by an FDA priority voucher), then ACHV could achieve an annual revenue run-rate exceeding $300M-$500M within 3-5 years, justifying a market capitalization of $3B-$5B (5x-10x current valuation). This is bullish because the market has not yet fully priced in the certainty of approval and the substantial dual-indication market potential for a de-risked asset with clear commercialization runway.
Is ACHV Stock Undervalued?
Unlock the full AI analysis for ACHV
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ACHV Price Targets & Strategy
12-Month Target
$13.20
Bull Case
$20.00
Bear Case
$4.00
Valuation Basis
Target derived from analyst consensus, implying a potential market capitalization of $1.37B (2.4x current) upon successful NDA approval and initial commercialization ramp of cytisinicline.
Entry Strategy
Consider dollar-cost averaging in the range of $5.00-$6.00, especially on any dips prior to the PDUFA decision. Optimal entry might be on a slight pullback if regulatory approval is highly anticipated but not fully priced in.
Exit Strategy
Take initial profits at $10.00-$13.20, with a stop-loss at $4.00, particularly if the PDUFA outcome is negative.
Portfolio Allocation
5-10% for aggressive risk tolerance given the binary nature of upcoming catalysts; 1-3% for moderate risk.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is ACHV Financially Healthy?
Profitability
Operating Margin
-106.51%
Net Margin
-94.67%
Return on Equity
-193.49%
Revenue Growth
-89.25%
EPS
$-1.11
Balance Sheet
Current Ratio
4.39
Quick Ratio
4.01
Debt/Equity
0.69
Cash & Equivalents
$29.30M
Other
Beta (Volatility)
2.32
Does ACHV Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability hinges on the remaining patent life for cytisinicline, the strength of its clinical data supporting differentiation, and the duration of any regulatory exclusivities (e.g., 5-7 years for a new chemical entity in the U.S.). The FDA voucher for vaping cessation could further strengthen its regulatory moat for that indication.
Moat Erosion Risks
- •Patent expiry or successful challenges to intellectual property, leading to generic competition.
- •Emergence of new, highly effective, and safer competitive therapies from larger pharmaceutical companies.
- •Inability to secure or maintain regulatory exclusivities in key markets.
ACHV Competitive Moat Analysis
Sign up to see competitive advantages
ACHV Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish; retail investors are likely attentive to the imminent PDUFA decision and recent positive regulatory news.
Institutional Sentiment
Positive; indicated by the $13.20 average analyst price target and the significant institutional investment in the recent $168.6M private placement.
Insider Activity (Form 4)
No verified Form 4 insider trades found in the provided research for the last 90 days. Executive and board changes were noted but are not transactions.
Options Flow
Normal options activity, as no specific data indicating unusual put/call ratios or large block trades was provided.
Earnings Intelligence
Next Earnings
2026-08-06
Surprise Probability
Medium
Historical Earnings Pattern
For pre-commercial biotechs like ACHV, regulatory announcements and clinical trial updates typically have a far greater impact on stock price than quarterly financial results, which primarily reflect burn rate.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (no direct 'best-in-class' competitor named in the provided data, but historical competitors include Pfizer (Chantix) and GSK (Zyban))
Market Share Trend
Not applicable; the company is pre-commercial and seeking to establish initial market share.
Valuation vs Peers
Not meaningfully comparable on traditional earnings multiples (P/E, EV/EBITDA) due to pre-revenue status and significant losses. Valuation is forward-looking based on pipeline potential.
Competitive Advantages
- •Favorable safety profile of cytisinicline (e.g., low nausea incidence of 2.5% over 52 weeks in recent data).
- •Potential to be a first-in-class non-nicotine treatment for vaping cessation, supported by an FDA Commissioner’s National Priority Voucher.
- •Strong efficacy data for smoking cessation, positioning it as a potentially superior alternative to existing therapies.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive ACHV Stock Higher?
Near-Term (0-6 months)
- •June 20, 2026 PDUFA date: FDA decision on cytisinicline for smoking cessation NDA. Approval would trigger significant stock re-rating and validate commercialization path.
- •August 6, 2026: Q2 2026 earnings report. Key to watch: cash burn rate (Q1 2026 operating expenses were $10.5M) and any commentary on PDUFA outcome if announced.
Medium-Term (6-18 months)
- •H1 2027: Initiation of commercial sales and initial market penetration for cytisinicline in smoking cessation, targeting first annual revenue milestones.
- •H2 2027: Potential NDA filing/submission for cytisinicline for vaping cessation, leveraging the FDA Commissioner’s National Priority Voucher for expedited review.
Long-Term (18+ months)
- •2028-2029: Cytisinicline achieves peak annual sales exceeding $300M-$500M across smoking and vaping cessation, establishing market leadership and justifying a significantly higher valuation.
- •2029-2030: Exploration and advancement of new indications or pipeline assets, leveraging established commercial infrastructure and R&D expertise.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for ACHV?
- ✓
FDA approval decision for cytisinicline by June 20, 2026 (CRL vs. approval).
- ✓
First full quarter of cytisinicline sales post-approval; crossing $10M-$15M in sales would indicate a successful initial commercial launch.
- ✓
Updates on the vaping cessation program, particularly the timing of an NDA submission and regulatory feedback.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Achieve Life Sciences Inc Makes Money
Achieve Life Sciences is a clinical-stage pharmaceutical company dedicated to developing and commercializing cytisinicline, a plant-based therapeutic, for nicotine dependence conditions such as smoking cessation and vaping cessation. The company currently generates no product revenue, with its business model entirely focused on advancing cytisinicline through clinical trials and regulatory approval processes in anticipation of future commercial sales or licensing agreements in the pharmaceutical market.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Achieve Life Sciences Inc (ACHV)?
As of June 15, 2026, Achieve Life Sciences Inc has a DVR Score of 8.1 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Achieve Life Sciences Inc?
Achieve Life Sciences Inc's market capitalization is approximately $566.7M..
What is the risk level for ACHV stock?
Our analysis rates Achieve Life Sciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Achieve Life Sciences Inc's revenue growing?
Achieve Life Sciences Inc has reported revenue growth of -89.3%. Revenue has been declining, which warrants closer examination.
Is ACHV stock profitable?
Achieve Life Sciences Inc has a profit margin of -94.7%. The company is currently unprofitable.
How often is the ACHV DVR analysis updated?
Our AI-powered analysis of Achieve Life Sciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 15, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ACHV (Achieve Life Sciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.